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3-O-(3,3-Dimethylsuccinyl) betulinic acid (DSB), also known as PA-457, bevirimat (BVM), or MPC-4326,
is a novel HIV-1 maturation inhibitor. Unlike protease inhibitors, BVM blocks the cleavage of the Gag capsid
precursor (CA-SP1) to mature capsid (CA) protein, resulting in the release of immature, noninfectious viral
particles. Despite the novel mechanism of action and initial progress made in small-scale clinical trials, further
development of bevirimat has encountered unexpected challenges, because patients whose viruses contain
genetic polymorphisms in the Gag SP1 (positions 6 to 8) protein do not generally respond well to BVM
treatment. To better define the role of amino acid residues in the HIV-1 Gag SP1 protein that are involved in
natural polymorphisms to confer resistance to the HIV-1 maturation inhibitor BVM, a series of Gag SP1
chimeras involving BVM-sensitive (subtype B) and BVM-resistant (subtype C) viruses was generated and
characterized for sensitivity to BVM. We show that SP1 residue 7 of the Gag protein is a primary determinant
of SP1 polymorphism-associated drug resistance to BVM.
3-O-(3,3-Dimethylsuccinyl) betulinic acid (DSB), also known
as bevirimat (BVM), is a potent inhibitor of HIV-1 maturation
(7, 8, 20, 21). BVM targets the HIV-1 Gag CA-SP1 boundary
region by blocking viral protease cleavage of SP1 from the
CA-SP1 precursor and inhibiting release of the mature CA
protein, which is the final step required for virion maturation.
Despite the novel mechanism of action and initial progress
made in small-scale clinical trials (11–13, 17), further develop-
ment of BVM has encountered unexpected challenges in the
clinical setting, because patients whose viruses contain genetic
polymorphisms in the Gag SP1 (positions 6 to 8) protein do not
respond well to BVM treatment (3, 10, 14, 16). These three
residues (glutamine-valine-threonine [QVT]) are referred to
as the SP1 polymorphism motif. Interestingly, these naturally
occurring mutations that confer intrinsic resistance to BVM
were not identified by in vitro drug resistance selection exper-
iments and are not located in the region immediately flanking
the CA-SP1 cleavage site (2, 7, 8). Extensive in vitro drug
selection experiments identified six amino acid changes (prox-
imal to the CA-SP1 cleavage site) that independently confer
BVM resistance (2). Three substitutions were located at the 1st
and 3rd residues of SP1 (A1V, A3V, and A3T), and three
substitutions were identified at the extreme C terminus of CA
(H226Y, L231M, and L231F).
There are extensive data on HIV-1 subtype B viruses
and their representative molecular clone pNL4-3 concern-
ing BVM’s mechanism of action and antiviral activity (2, 4, 7,
8, 20, 21). In contrast, HIV-1 non-B subtypes and derived
molecular clones have received less attention, despite knowl-
edge that these non-B subtypes are responsible for nearly 90%
of the current worldwide HIV-1 pandemic (6, 19). Addition-
ally, we noted that non-B subtypes exhibit more frequent
changes in the identified SP1 polymorphism motif than B
subtype viruses do. These non-B viruses therefore provide
important systems for studying the impact of these naturally
occurring polymorphisms on BVM antiviral activity and the
mechanism of BVM action. The aims of the present study were
to examine the influence of SP1 polymorphisms on BVM-
mediated blockade of CA-SP1 processing (a hallmark of BVM
activity) in HIV-1 subtype C and to determine which posi-
tion(s) within the SP1 polymorphism motif is integral in con-
ferring resistance to BVM in HIV-1.
MATERIALS AND METHODS
Construction of HIV-1 DNA constructs. To investigate the influence of SP1
polymorphisms on BVM-mediated antiviral activity in subtype C viruses, we
generated two chimeras (Fig. 1B), designated NL/MJ4 and NL/1084i, that con-
tained a representative CA-SP1-NC segment (containing the C-terminal 126
residues of CA, complete SP1, and the N-terminal 29 residues of NC) from
corresponding BVM-resistant subtype C clone MJ4 (NIH AIDS Research and
Reference Reagent Program) or 1084i (a gift of Ruth M. Ruprecht) in the
context of the BVM-sensitive NL4-3 clone (NIH AIDS Research and Reference
Reagent Program). Chimeras were made by cloning the SpeI/ApaI double-
digested PCR-amplified CA-SP1-NC fragment of MJ4 or 1084i into NL4-3 which
had been digested completely with SpeI/ApaI. These two chimeras, together with
NL4-3, were then used as templates to carry out extensive mutagenesis to gen-
erate panels of single and double substitution mutations as shown in Fig. 2 and
Fig. 3, respectively. All DNA mutagenesis was carried out using the PCR–
overlapping-PCR strategy and other standard molecular cloning approaches.
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Each clone was sequenced to confirm the sequence of the inserted Gag CA-
SP1-NC segment.
SDS-PAGE and Western blotting. To address the effects of SP1 polymor-
phisms on the ability of BVM to inhibit CA-SP1 processing, COS-1 cells were
transfected with parental HIV-1 pNL4-3 and various mutant proviral DNAs, as
indicated. Transfection was performed by using TransIT-LT1 (Mirus, Madison,
WI) following the procedure outlined by the manufacturer. BVM at a concen-
tration of 1 g/ml or 5 g/ml or dimethyl sulfoxide (DMSO) (no-drug control)
was maintained throughout the period of the culture, and SDS-PAGE and
Western blotting to analyze viral proteins derived from these cultures were
performed as described previously (7, 8).
Briefly, at 48 h posttransfection, culture medium containing viral particles was
collected and clarified by centrifugation at 4°C for 20 min at 2,000 rpm, using a
Sorvall RT 6000B centrifuge. Virus-containing supernatants were then concen-
trated through a 20% sucrose cushion in a microcentrifuge at 4°C for 120 min at
13,000 rpm, and pellets were resuspended in lysis buffer (150 mM Tris-HCl, 5%
Triton X-100, 1% deoxycholate, 0.1% SDS, pH 8.0). Viral proteins were then
separated by 12% SDS-PAGE and transferred to a nitrocellulose membrane
(Invitrogen), followed by blocking in phosphate-buffered saline (PBS) containing
0.5% Tween and 5% dry milk powder. The membrane was incubated with pooled
immunoglobulin from HIV-1-infected patients (HIV-Ig) (NIH AIDS Research
and Reference Reagent Program) and hybridized with goat anti-human–horse-
radish peroxidase (Sigma). The immune complex was visualized using an ECL
system (Pierce, Rockford, IL) according to the instructions provided by the
manufacturer. Protein bands were analyzed by ImageJ software (http://rsbweb
.nih.gov/ij/) to quantify the percentage of CA-SP1 relative to total CA-SP1 plus
CA. The same exposure time was used to develop films.
Single-cycle infectivity assay. We used vesicular stomatitis virus glycoprotein
(VSV-G)-pseudotyped HIV-1 particles coupled with the TZM-bl indicator cell
line (NIH AIDS Research and Reference Reagent Program) to measure the
50% effective concentrations (EC50s) of BVM for the above chimeras. An HIV-1
Env-defective reporter clone (NIH AIDS Research and Reference Reagent
Program) that is widely used for the phenotypic analysis of HIV-1 drug resistance
was used in our study. This clone, designated pNL4-3-ENV-EGFP, is derived
from the HIV-1 proviral clone pNL4-3 but encodes a form of enhanced green
fluorescent protein (EGFP) in the Env open reading frame. The SpeI/ApaI
cloning strategy described above was used to introduce CA-SP1-NC segments
from NL4-3 and NL/MJ4 chimeras into pNL4-3-ENV-EGFP.
VSV-G-pseudotyped HIV-1 stocks were produced in COS-1 cells treated with
or without BVM as described previously. Briefly, COS-1 cells were cotransfected
with wild-type (WT) NL4-3 or derived chimeras and VSV-G by use of TransIT-
LT1 (Mirus) in the presence or absence of BVM. Four 10-fold serial dilutions
(0.01, 0.1, 1.0, and 10 g/ml) were tested in triplicate. Forty-eight hours after
transfection, supernatants containing VSV-G-pseudotyped HIV-1 were col-
lected. Cell debris was removed from the supernatant by spinning at 450  g for
5 min and filtering through filters (Millipore). Viral supernatants were then used
for infection of TZM-bl indicator cells in a 96-well flat-bottom plate at 3  103
cells/well. Infections were carried out for 2 h in the presence of 10 g/ml
DEAE-dextran, and luciferase activity was then measured at 48 h postinfection,
using a luciferase assay system (Promega). Linear regression was used to deter-
mine the EC50s of BVM.
RESULTS AND DISCUSSION
For this study, we utilized two well-characterized subtype C
molecular clones (5, 15), termed 1084i and MJ4, which have
SP1 polymorphisms at 7 and 8 positions, respectively, but con-
tain no known drug resistance-conferring mutations identified
previously in the subtype B NL4-3 clone. Because similar SP1
polymorphism patterns were witnessed for MJ4 and 1084i (Fig.
FIG. 1. Western blot analysis of virion-associated Gag derived from COS-1 cells transfected with proviral DNA of NL4-3, 1084i, or their
derivatives in the absence or presence of BVM. The top diagram in panel A shows the amino acid sequences of the CA-SP1 boundary domain for
subtype B NL4-3 and the two subtype C viruses (1084i and MJ4). Gag SP1 residues 6 to 8 (glutamine-valine-threonine [QVT]), termed the SP1
polymorphism motif, are underlined. The residues previously identified as conferring BVM resistance in vitro are shown in bold (2). Dashes
represent residues that are identical to the parental NL4-3 sequence. The top diagram in panel B shows the panel of chimeric Gag constructs used
in this study. NL4-3 domains are in white, while 1084i and MJ4 domains are represented in gray. Two restriction enzymes (SpeI and ApaI) were
used for cloning and are indicated schematically by arrows at their corresponding locations in the Gag domains. A previously published protocol
was used to address the effect of BVM on Gag CA-SP1 processing (8). COS-1 cells were transfected with proviral NL4-3, 1084i, or their
derivatives and cultured in the absence or presence of the indicated concentrations of BVM. BVM concentrations in g/ml can be converted
to molar concentrations by using the equation 1 g/ml  1.71 M. At 2 days posttransfection, equal volumes of supernatant from each
culture were collected and then concentrated through a 20% sucrose cushion in a microcentrifuge at 4°C for 120 min at 13,000 rpm. Viral
pellets were resuspended in lysis buffer (150 mM Tris-HCl, 5% Triton X-100, 1% deoxycholate, 0.1% sodium dodecyl sulfate, pH 8.0). Viral
proteins were separated by 12% SDS-PAGE and transferred to a nitrocellulose membrane (Pierce). Following transfer, membranes were
blocked in PBS containing 0.5% Tween and 5% dry milk powder. The membrane was then incubated with HIV-Ig (obtained through the NIH
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID) and hybridized with goat anti-human–horseradish peroxidase
(Abcam). The immune complex was visualized using an ECL system (Pierce) according to the instructions provided by the manufacturer. The
positions of virally encoded proteins CA (p24) and CA-SP1 (CA-SP1) are indicated. Note the accumulation of CA-SP1 in the presence of BVM
in NL4-3 but not in 1084i or strains expressing chimeric Gag between NL4-3 and MJ4 (NL/MJ4) or NL4-3 and 1084i (NL/1094i). Due to high
protein expression levels by NL4-3, a gel with a 1-min exposure time is shown. The data presented in this figure are representative of at least four
independent experiments.
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1A), we opted to use subtype C clone p1084i in our initial
experiment. We employed a Western blot-based HIV-1 Gag
processing assay previously developed by our group to assess
the BVM susceptibility of these non-subtype B viruses (8). The
Gag processing experiment specifically measures the effect of
BVM on CA-SP1 cleavage and the ability of the compound to
inhibit the release of mature CA protein. A strong correlation
between the Gag processing experiment and the cell-based
replication assay has been established in characterizing BVM
activity against HIV-1 (8). For Gag processing experiments,
COS-1 cells were transfected with the parental or SP1 variant
proviral DNA in the presence of BVM or a DMSO control. At
48 h posttransfection, virus was harvested from the cell culture
supernatant, and the Gag processing profile for each virus was
analyzed and compared to Gag processing exhibited in the
absence of compound (DMSO control).
NL4-3 CA-SP1 (p25) processing in virions was significantly
blocked by BVM, similar to observations in our previous stud-
ies (Fig. 1A) (7, 8). In contrast, inhibition of CA-SP1 process-
ing was not observed in BVM-treated 1084i virions, indicating
that this subtype C virus was resistant to BVM. Because 1084i
virus itself lacks any previously identified drug resistance-con-
ferring mutations, it is likely that mutations within the SP1
polymorphism motif were responsible for the observed BVM
resistance, as demonstrated previously for subtype B variants
(3, 14, 18). We noticed variability in viral particle production
between subtype C and subtype B viruses that may affect our
assay readout. To minimize the variability and ensure that we
had a comparable virus particle production system for analysis,
we generated two chimeras, designated NL/MJ4 and NL/1084i,
that contained a representative CA-SP1-NC segment (contain-
ing a portion of C-terminal CA, complete SP1, and a portion of
N-terminal NC) from corresponding BVM-resistant viruses in
the context of the NL4-3 backbone. The observation that these
Gag CA-SP1 chimeras, like their parental clones, exhibited
reduced BVM sensitivity supported the utilization of these
chimeras for further study (Fig. 1B).
Next, two approaches, examining the loss or gain of function,
were pursued in parallel to determine the effect of the muta-
tions on BVM activity in Gag CA-SP1 chimeras. The percent-
age of CA-SP1 relative to total CA-SP1 plus CA observed in
BVM-treated virions was calculated and used to determine dif-
ferential susceptibility to BVM treatment. The first approach
(loss of function) involved the creation of alanine-scanning mu-
tations across the SP1 polymorphism motif (QVT), and the re-
sulting mutants were characterized for sensitivity to BVM in
the Gag processing experiment. In agreement with a recent
study (3), only SP1 residue seven (SP1-V7), not the other two
residues, was shown to be critical for determining BVM anti-
viral activity, as the presence of a V7A mutation sufficiently
conferred BVM resistance in Gag processing experiments,
while Q6A and V8A mutations had no apparent effect on
BVM activity (Fig. 2). These data provide further evidence that
FIG. 2. Western blot analysis of the effect of mutations within the SP1 polymorphism motif on BVM’s activity in inhibiting the conversion of
the capsid precursor, CA-SP1, to mature capsid protein. (A) Mutations introduced into the SP1 polymorphism motif (underlined). Dashes
represent residues that are identical to the parental NL4-3 sequence. COS-1 cells were transfected with both parental HIV-1 pNL4-3 and alanine
substitution mutant proviral DNAs as described in the legend to Fig. 1. BVM at the indicated concentrations or DMSO (no-drug control) was
maintained throughout the period of the culture. For BVM, 1 g/ml  1.71 M. (B) SDS-PAGE and Western blot analysis of viral proteins derived
from these cultures were performed as described in the legend to Fig. 1. (C) Protein bands were analyzed by ImageJ software (http://rsbweb.nih
.gov/ij/) to quantify the percentage of CA-SP1 relative to total CA-SP1 plus CA. All data shown are means and standard deviations for three
independent experiments performed in duplicate.
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genetic polymorphisms at the seventh position of SP1 are par-
ticularly detrimental to BVM-mediated antiviral activity.
Our second approach involved the generation of a panel of
either single or multiple substitution mutants targeting SP1
residues 7 and 8 in which the SP1 residues from the BVM-
sensitive NL4-3 virus were inserted into the analogous posi-
tions of the SP1 proteins of the BVM-resistant chimeras (Fig.
3). These mutants were then characterized for sensitivity to
BVM in studies that measured the effect of the compound on
CA-SP1 cleavage. Gain-of-function studies were used to define
the specific residues responsible for drug resistance. As
summarized in Fig. 3, these experiments revealed a striking
similarity in compound sensitivity rendered by SP1 residues
derived from BVM-sensitive NL4-3 between the two BVM-
resistant NL4-3/non-subtype B chimeras. For example, the
A7V substitution conferred to both Gag CA-SP1 chimeras
(NL/1084i and NL/MJ4) approximately 100% of the BVM
activity observed in NL4-3, as well as a similar extent of CA-
SP1 precursor accumulation in the presence of 1 g/ml BVM
(7% CA-SP1 accumulation) (cf. Fig. 2 and 3) or 5 g/ml
BVM (20% CA-SP1 accumulation) (cf. Fig. 2 and 3). Al-
though the threonine substitution at SP1 residue 8 alone was
insufficient to confer drug sensitivity in our assays, double
replacement of SP1 residues 7 and 8 by VT residues signifi-
cantly enhanced the sensitivity of these two NL4-3/C chimeras
(NL/1084i and NL/MJ4) to BVM (showing an approximate
2-fold increase) (Fig. 3C), indicating a synergetic effect of the
two positions in regulating BVM activity.
The Gag processing experiments specifically measured the
effect of BVM on CA-SP1 cleavage and the ability of the com-
pound to inhibit the release of mature CA protein. To further
TABLE 1. In vitro activity of BVM against different viruses in
single-cycle infectivity assay
Virus BVM EC50 (M)a
NL4-3...................................................................................0.039  0.005
NL4-3(Q6A) .......................................................................0.031  0.009
NL4-3(V7A) ....................................................................... 17.1b
NL4-3(T8A)........................................................................0.038  0.009
NL/MJ4 ............................................................................... 17.1b
NL/MJ4(A7V) ....................................................................3.261  1.739
NL/MJ4(N8T)..................................................................... 17.1b
NL/MJ4(AN78VT) ............................................................0.125  0.053
a Antiviral activity was determined after infection of TZM-bl indicator cells
with VSV-G-pseudotyped HIV-1 as described in Materials and Methods. Values
represent means  standard deviations for two independent experiments per-
formed in triplicate.
b The highest drug concentration tested in this study.
FIG. 3. Importance of SP1 residues 7 and 8 in the modulation of BVM activity in inhibiting the conversion of the capsid precursor, CA-SP1,
to mature capsid protein. (A) Panel of Gag SP1 chimeras constructed between NL4-3 and MJ4 or between NL4-3 and 1084i and containing various
mutations targeting the SP1 polymorphism motif (underlined). Dashes represent residues that are identical to the parental virus (NL/MJ4 or
NL/1084i) sequence. (B) COS-1 cells were transfected with the indicated mutant proviral DNAs as described in the legend to Fig. 1. BVM or
DMSO (no-drug control) was maintained throughout the period of the culture, and SDS-PAGE and Western blot analysis of viral proteins
obtained from the cultures were performed as described in the legend to Fig. 1. (C) Protein bands were analyzed by ImageJ software (http:
//rsbweb.nih.gov/ij/) to quantify the percentage of CA-SP1 relative to total CA-SP1 plus CA. All data shown are means and standard deviations
for three independent experiments performed in duplicate.
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characterize the effect of BVM on these chimeras, we em-
ployed a single-cycle infectivity assay involving VSV-G-pseu-
dotyped HIV-1 particles and the TZM-bl indicator cell line. As
summarized in Table 1, the results of this assay correlated well
with those obtained in the Gag processing experiment. For
example, parental EC50s of BVM were consistently observed
with NL4-3(Q6A), NL4-3(T8A), and NL/MJ4(AN78VT),
which exhibited WT-like BVM sensitivity in the Gag process-
ing experiment. Additionally, three mutants, NL4-3(V7A),
NL/MJ4, and NL/MJ4(N8T), identified as BVM resistant in
the Gag processing experiment, lacked compound sensitivity in
the assay, with EC50s of 17.1 M. The NL/MJ4(A7V) mutant
was unique in that it exhibited intermediate sensitivity to com-
pound treatment, with an EC50 of around 3.261  1.739 M.
Interestingly, NL/MJ4(AN78VT), with an additional substitu-
tion at SP1 residue 8, exhibited a WT-like EC50. This result
further strengthens our previous interpretation of a synergetic
effect of SP1 residues 7 and 8 in regulating BVM activity.
As summarized in Table 2, we performed a detailed analysis
of the prevalence of SP1 polymorphisms in both HIV-1 sub-
type C viruses (n  1,174) and HIV-1 subtype B viruses (n 
2,111). The SP1 position 7-associated polymorphism was pre-
dominant in subtype C viruses and less so in subtype B viruses.
For example, the V7A mutation (conferring BVM resistance)
was present in 70.3% of subtype C viruses, while the same
mutation was identified in only 16.8% of subtype B viruses.
Thus, the naturally occurring SP1-V7A polymorphism, partic-
ularly in HIV-1 subtype C viruses, constitutes a significant
obstacle to clinical testing of BVM, as viruses with this poly-
morphism display robust BVM resistance.
It should be noted that the SP1 polymorphism residues iden-
tified in this study and elsewhere are located at the very C
terminus of a CA-SP1 junction region exhibiting an 	-helical
secondary structure (1, 9). We previously proposed that BVM
might bind to this putative helical structure of the Gag CA-SP1
protein and therefore disrupt CA-SP1 processing without in-
terfering with the function of the putative structural element
involved in virus assembly and budding (8). A possible expla-
nation for the observed SP1 polymorphism-associated drug
resistance involves a mechanism in which mutations at posi-
tions 7 and 8 in SP1 may alter the helical structure and con-
sequently affect BVM interaction with the helix, leading to
drug resistance. A more complete understanding of the struc-
ture and function of this helical structure of Gag CA-SP1 in
HIV-1 biology and the mechanism of BVM action will be
required before more definitive conclusions can be drawn.
The results presented here continue to support the theme
that amino acid variation in the SP1 polymorphism motif in-
hibits the ability of the HIV-1 maturation inhibitor bevirimat
to block CA-SP1 cleavage (3, 14, 18). Our results extend pre-
vious findings by demonstrating that SP1 residue 7 is a primary
determinant of SP1 polymorphism-associated drug resistance,
and an additional mutation at SP1 residue 8 seems to poten-
tiate a threshold effect defined by SP1 residue 7. The results
also extend our previous characterization of the molecular
determinants of BVM susceptibility to include Gag residues
that are located in the middle region of SP1, distal from the
CA-SP1 cleavage site. Future studies to address the mecha-
nisms by which SP1 polymorphisms confer drug resistance
should allow for a better understanding of the molecular target
for the HIV-1 maturation inhibitor bevirimat and should aid in
the discovery and design of additional active maturation inhib-
itors effective against both WT HIV-1 and resistant viruses.
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